CLIONA ROONEY to Immunotherapy
This is a "connection" page, showing publications CLIONA ROONEY has written about Immunotherapy.
Connection Strength
3.057
-
Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy. J Immunother Cancer. 2023 04; 11(4).
Score: 0.545
-
PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther. 2011 Dec; 19(12):2133-43.
Score: 0.242
-
Hitchhiker's guide to the T cell. Nat Med. 2005 Oct; 11(10):1051-2.
Score: 0.162
-
Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas. Blood Adv. 2025 Apr 08; 9(7):1658-1669.
Score: 0.157
-
Options for T-cell based therapies. Vox Sang. 2004 Jul; 87 Suppl 2:230-4.
Score: 0.149
-
Immunotherapy for post-transplant lymphoproliferative disease. Br J Haematol. 2002 Sep; 118(3):728-40.
Score: 0.131
-
A Costimulatory CAR Improves TCR-based Cancer Immunotherapy. Cancer Immunol Res. 2022 04 01; 10(4):512-524.
Score: 0.127
-
Immune therapy for EBV infections after hemopoietic stem-cell transplant. Cytotherapy. 2002; 4(5):433-4.
Score: 0.125
-
Immunotherapy for Hodgkin's disease. Ann Hematol. 2002; 81 Suppl 2:S39-42.
Score: 0.125
-
Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy. Cytotherapy. 2019 02; 21(2):212-223.
Score: 0.100
-
Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. Expert Opin Biol Ther. 2018 06; 18(6):653-664.
Score: 0.097
-
Antigen-specific T cell therapies for cancer. Hum Mol Genet. 2015 Oct 15; 24(R1):R67-73.
Score: 0.080
-
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015 Jun 18; 125(25):3905-16.
Score: 0.079
-
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015 May 20; 33(15):1688-96.
Score: 0.078
-
Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. Mol Ther. 2015 Mar; 23(3):602-8.
Score: 0.077
-
Harnessing the immune system to potentiate oncolytics. Mol Ther. 2014 Feb; 22(2):239-240.
Score: 0.072
-
Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther. 2011 Dec; 19(12):2258-68.
Score: 0.061
-
Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther. 2011 Jun; 19(6):1008-16.
Score: 0.060
-
Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation. Immunotherapy. 2010 Sep; 2(5):663-71.
Score: 0.057
-
Developments in clinical cell therapy. Cytotherapy. 2010 May; 12(3):425-8.
Score: 0.056
-
Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leuk Lymphoma. 2010 May; 51(5):870-80.
Score: 0.056
-
Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther. 2009 Sep; 17(9):1616-25.
Score: 0.053
-
Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther. 2009 Oct; 17(10):1779-87.
Score: 0.052
-
Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function. Cancer Res. 2007 Sep 01; 67(17):8335-43.
Score: 0.046
-
Immunotherapy for Epstein-Barr virus-associated cancers in children. Oncologist. 2003; 8(1):83-98.
Score: 0.033
-
Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. 2002 May 01; 99(9):3179-87.
Score: 0.032
-
Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. Blood Adv. 2022 02 08; 6(3):891-901.
Score: 0.031
-
Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol. 1998; 9 Suppl 5:S129-32.
Score: 0.024
-
Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity. Mol Med Today. 1997 Jan; 3(1):24-30.
Score: 0.022
-
Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy. Mol Ther. 2015 Feb; 23(2):387-95.
Score: 0.019
-
Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. Mol Ther. 2014 Jun; 22(6):1134-1138.
Score: 0.018
-
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013 Mar; 19(3):329-36.
Score: 0.017
-
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011 May; 121(5):1822-6.
Score: 0.015
-
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008 Nov; 14(11):1264-70.
Score: 0.013
-
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007 Oct 01; 110(7):2620-30.
Score: 0.011
-
In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006 May; 47(5):837-42.
Score: 0.011
-
Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol. 2005 Sep 15; 175(6):4137-47.
Score: 0.010
-
Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy. Exp Hematol. 2001 Aug; 29(8):952-61.
Score: 0.008
-
Autoimmune disease induced by dendritic cell immunization against leukemia. Leuk Res. 1999 Jun; 23(6):549-57.
Score: 0.007